Supplementary Materials

The PDF file includes:

  • Fig. S1. Validation of cell of origin subtyping.
  • Fig. S2. Comparison of outcome in CHOP-treated patients with DLBCL stratified by cell of origin subtype and 18q21 gain.
  • Fig. S3. Recurrently mutated genes enriched in the ABC-like DLBCL subtype.
  • Fig. S4. Expression patterns of TCF3 and TCF4 in normal and malignant B cells.
  • Fig. S5. Tetracycline induction of TCF4 expression.
  • Fig. S6. ChIP-seq peaks for TCF4.
  • Fig. S7. Cellular localization of TCF4-induced IgM.
  • Fig. S8. Quantification of TCF4-induced MYC and BCL2 protein expression.
  • Fig. S9. shRNA-mediated knockdown of TCF4.
  • Fig. S10. BRD4 regulates TCF4 in DLBCL cell lines.
  • Fig. S11. Western blot quantification of triplicate BET inhibitor experiments.
  • Fig. S12. ARV771 induces apoptosis in RIVA and U2932 cell lines.
  • Fig. S13. Effect of ARV-771 on IgM expression in GCB-like DLBCL cell lines.
  • References (5763)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 contains the following supplementary tables:
  • Table S1 (Microsoft Excel format). Genomic and clinical data from DLBCL tumors included in this study.
  • Table S2 (Microsoft Excel format). NGS statistics.
  • Table S3 (Microsoft Excel format). Genes in GISTIC peaks.
  • Table S4 (Microsoft Excel format). Cell of origin association of GISTIC peaks.
  • Table S5 (Microsoft Excel format). Cell of origin association of recurrently mutated genes.
  • Table S6 (Microsoft Excel format). Integrative analysis of DNA CNAs.
  • Table S7 (Microsoft Excel format). Differential gene expression analysis of ABC-like tumors with or without TCF4 copy gain.
  • Table S8 (Microsoft Excel format). ChIP-seq peaks for TCF4 signature genes.
  • Table S9 (Microsoft Excel format). Differentially expressed genes following ARV-771 treatment.
  • Table S10 (Microsoft Excel format). Primer sequences.